ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
CALL TO ACTION: Stop the FDA from restricting compounded hormone therapy!
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 188640" data-attributes="member: 3"><p>From CompoundingToday.com</p><p></p><p><strong>The "Clinical Utility" of Compounded Bioidentical Hormone Therapy (cBHT)</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>"Six Recommendations"</strong></p><p></p><table class='post-table ' style='width: 100%'><tr><td ><p>Here are the six general recommendations from the NASEM HRT Report:<br /> <ol> <li data-xf-list-type="ol">Prescribers and compounding pharmacists should restrict the use of [compounded bioidentical hormone therapy] cBHT preparations.<br /> <br /> </li> <li data-xf-list-type="ol">The (FDA) Pharmacy Compounding Advisory Committee should review select bioidentical hormone therapies and dosage forms as candidates for the FDA Difficult to Compound List.<br /> <br /> </li> <li data-xf-list-type="ol">Improve education for prescribers and pharmacists who market, prescribe, compound, and dispense cBHT preparations.<br /> <br /> </li> <li data-xf-list-type="ol">Additional federal and state-level oversight is needed to better address public health and clinical concerns regarding the safety and effectiveness of cBHT.<br /> <br /> </li> <li data-xf-list-type="ol">Collect and disclose conflicts of interest.<br /> <br /> </li> <li data-xf-list-type="ol">Strengthen and expand the evidence base on safety, effectiveness, and use of cBHT preparations.</li> </ol></p></td></tr></table>Each of the "Recommendations" is accompanied with additional explanations. We will include two Recommendations with explanations in three separate Newsletters. We have presented these previously, but the ramifications are so great that we will repeat them.</p><table class='post-table ' style='width: 100%'><tr><td ><p><strong>RECOMMENDATION 1</strong><br /> <strong>Restrict the use of cBHT preparations.</strong><br /> <br /> Prescribers should restrict the use of cBHT preparations to the following: documented allergy to an active pharmaceutical ingredient or excipient of FDA-approved drug product, or a documented requirement for a different dosage form. Patient preference alone should not determine the use of cBHT preparations.<br /> In general, the potency of cBHT doses should not exceed those of FDA-approved hormone therapy products because of potential safety concerns. Any use of cBHT, including therapy for gender dysphoria, should align with established clinical guidance and require documentation of shared decision making and rigorous monitoring for long-term risks.<br /> Prescribers and compounding pharmacists should clearly explain the limited evidence-based information about the safety and effectiveness of cBHT preparations. They should inform patients that compounded preparations are not FDA-approved.<br /> <br /></p></td></tr></table><table class='post-table ' style='width: 100%'><tr><td ><p><strong>EDITOR'S BRIEF COMMENT ON RECOMMENDATION 1</strong><br /> This recommendation encroaches on the physician-patient relationship and provides no substantive reason for "restricting" the use of cBHT preparations. Patients generally request cBHT preparations after trying FDA-approved products without satisfactory relief. Dosing is dependent upon the physicians' judgment and patient response and monitoring. After decades of use of hormone products, their clinical safety and effectiveness have been well-documented.</p></td></tr></table><table class='post-table ' style='width: 100%'><tr><td ><p><strong>RECOMMENDATION 2</strong><br /> <strong>Review select bioidentical hormone therapies and dosage forms as candidates for the FDA Difficult to Compound List.</strong><br /> The Pharmacy Compounding Advisory Committee should review the following bioidentical hormone therapies as candidates for FDA's Difficult to Compound List: estradiol, estrone, estradiol cypionate, estriol, dehydroepiandrosterone, pregnenolone, progesterone, testosterone, testosterone cypionate, and testosterone propionate. These candidates have safety and efficacy concerns related to the lack of bioavailability data and product-to-product variability as a result of drug formulation differences, stability, and quality control.<br /> The Pharmacy Compounding Advisory Committee should consider all cBHT preparations formulated in pellet dosage form as candidates for FDA's Difficult to Compound List.</p></td></tr></table><table class='post-table ' style='width: 100%'><tr><td ><p><strong>EDITOR'S COMMENT ON RECOMMENDATION 2</strong><br /> As is quite evident, the committee approached cBHT compounding from an FDA New-Drug-Application point of view which is not applicable to compounding individual cBHT prescriptions for individual patients. These preparations have been safely and effectively compounded for over 50 years with millions of treated and satisfied patients and are not difficult to compound. The FDA Difficult to Compound list should be limited to those products with demonstrated difficulty to compound leading to documented safety issues.</p></td></tr></table></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 188640, member: 3"] From CompoundingToday.com [B]The "Clinical Utility" of Compounded Bioidentical Hormone Therapy (cBHT) "Six Recommendations"[/B] [TABLE][TR][TD] Here are the six general recommendations from the NASEM HRT Report: [LIST=1] [*]Prescribers and compounding pharmacists should restrict the use of [compounded bioidentical hormone therapy] cBHT preparations. [*]The (FDA) Pharmacy Compounding Advisory Committee should review select bioidentical hormone therapies and dosage forms as candidates for the FDA Difficult to Compound List. [*]Improve education for prescribers and pharmacists who market, prescribe, compound, and dispense cBHT preparations. [*]Additional federal and state-level oversight is needed to better address public health and clinical concerns regarding the safety and effectiveness of cBHT. [*]Collect and disclose conflicts of interest. [*]Strengthen and expand the evidence base on safety, effectiveness, and use of cBHT preparations. [/LIST] [/TD][/TR][/TABLE] Each of the "Recommendations" is accompanied with additional explanations. We will include two Recommendations with explanations in three separate Newsletters. We have presented these previously, but the ramifications are so great that we will repeat them. [TABLE][TR][TD] [B]RECOMMENDATION 1 Restrict the use of cBHT preparations.[/B] Prescribers should restrict the use of cBHT preparations to the following: documented allergy to an active pharmaceutical ingredient or excipient of FDA-approved drug product, or a documented requirement for a different dosage form. Patient preference alone should not determine the use of cBHT preparations. In general, the potency of cBHT doses should not exceed those of FDA-approved hormone therapy products because of potential safety concerns. Any use of cBHT, including therapy for gender dysphoria, should align with established clinical guidance and require documentation of shared decision making and rigorous monitoring for long-term risks. Prescribers and compounding pharmacists should clearly explain the limited evidence-based information about the safety and effectiveness of cBHT preparations. They should inform patients that compounded preparations are not FDA-approved. [/TD][/TR][/TABLE] [TABLE][TR][TD] [B]EDITOR'S BRIEF COMMENT ON RECOMMENDATION 1[/B] This recommendation encroaches on the physician-patient relationship and provides no substantive reason for "restricting" the use of cBHT preparations. Patients generally request cBHT preparations after trying FDA-approved products without satisfactory relief. Dosing is dependent upon the physicians' judgment and patient response and monitoring. After decades of use of hormone products, their clinical safety and effectiveness have been well-documented. [/TD][/TR][/TABLE] [TABLE][TR][TD] [B]RECOMMENDATION 2 Review select bioidentical hormone therapies and dosage forms as candidates for the FDA Difficult to Compound List.[/B] The Pharmacy Compounding Advisory Committee should review the following bioidentical hormone therapies as candidates for FDA's Difficult to Compound List: estradiol, estrone, estradiol cypionate, estriol, dehydroepiandrosterone, pregnenolone, progesterone, testosterone, testosterone cypionate, and testosterone propionate. These candidates have safety and efficacy concerns related to the lack of bioavailability data and product-to-product variability as a result of drug formulation differences, stability, and quality control. The Pharmacy Compounding Advisory Committee should consider all cBHT preparations formulated in pellet dosage form as candidates for FDA's Difficult to Compound List. [/TD][/TR][/TABLE] [TABLE][TR][TD] [B]EDITOR'S COMMENT ON RECOMMENDATION 2[/B] As is quite evident, the committee approached cBHT compounding from an FDA New-Drug-Application point of view which is not applicable to compounding individual cBHT prescriptions for individual patients. These preparations have been safely and effectively compounded for over 50 years with millions of treated and satisfied patients and are not difficult to compound. The FDA Difficult to Compound list should be limited to those products with demonstrated difficulty to compound leading to documented safety issues. [/TD][/TR][/TABLE] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
CALL TO ACTION: Stop the FDA from restricting compounded hormone therapy!
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top